168 HR granisetron 0.129 MG/HR Transdermal System [Sancuso]
granisetron
RxCUI: 825005
What the CMS Formulary Data Shows for 168 HR granisetron 0.129 MG/HR Transdermal System [Sancuso]
Per the CMS 2026 Part D formulary file, 168 HR granisetron 0.129 MG/HR Transdermal System [Sancuso] (RxNorm concept RXCUI 825005, generic name granisetron) appears on 21 distinct formulary files spanning 1,045 Medicare Part D plan offerings - 20.6% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 5, with a cross-plan average of Tier 4.4.
Real-world access to 168 HR granisetron 0.129 MG/HR Transdermal System [Sancuso] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 14.3% require step therapy. 38.1% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 1,178 Part D beneficiaries filled 168 HR granisetron 0.129 MG/HR Transdermal System [Sancuso] in 2023, with total plan-and-beneficiary spending of $6,806,991 and an average per-beneficiary annual cost of $5,778.43. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry 168 HR granisetron 0.129 MG/HR Transdermal System [Sancuso] today.
Coverage Details
- Formularies covering
- 21
- Plans covering
- 1,045
- Coverage rate
- 20.6%
- Tier range
- Tier 1 – Tier 5
- Average tier
- Tier 4, Non-Preferred
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 14.3% of formularies
- Quantity limits
- 38.1% of formularies
2023 Medicare Spending
- Beneficiaries
- 1,178
- Total spending
- $6,806,991
- Avg per beneficiary
- $5,778.43
Tier Distribution Across Plans
Standalone Drug Plans (PDP) Covering 168 HR granisetron 0.129 MG/HR Transdermal System [Sancuso]
2 standalone prescription drug plans include this drug.
| Plan | Insurer | Tier | PA | ST | Premium | States |
|---|---|---|---|---|---|---|
| AARP Medicare Rx Preferred from UHC (PDP) | UNITEDHEALTHCARE INS. CO. & UHC INS. CO. OF NY | T5 | No | No | $0 | - |
| AARP Medicare Rx Preferred from UHC (PDP) | UNITEDHEALTHCARE INS. CO. & UHC INS. CO. OF NY | T5 | No | No | $0 | - |
Medicare Advantage Plans (MA-PD) Covering 168 HR granisetron 0.129 MG/HR Transdermal System [Sancuso]
98 Medicare Advantage plans with Part D drug coverage include this drug.
Frequently Asked Questions
Is 168 HR granisetron 0.129 MG/HR Transdermal System [Sancuso] covered by Medicare Part D?
Yes, 168 HR granisetron 0.129 MG/HR Transdermal System [Sancuso] is covered by 1,045 Medicare Part D plans (20.6% of all Part D formularies).
What tier is 168 HR granisetron 0.129 MG/HR Transdermal System [Sancuso] on Medicare Part D plans?
168 HR granisetron 0.129 MG/HR Transdermal System [Sancuso] averages Tier 4.4 across Part D plans, ranging from Tier 1 to Tier 5.
Does 168 HR granisetron 0.129 MG/HR Transdermal System [Sancuso] require prior authorization?
0% of Part D formularies require prior authorization for 168 HR granisetron 0.129 MG/HR Transdermal System [Sancuso]. Step therapy: 14.3%. Quantity limits: 38.1%.
How much does Medicare spend on 168 HR granisetron 0.129 MG/HR Transdermal System [Sancuso]?
In 2023, total Medicare Part D spending on 168 HR granisetron 0.129 MG/HR Transdermal System [Sancuso] was $6,806,991, covering 1,178 beneficiaries. The average spend per beneficiary was $5,778.43.
Read our methodology - how this data is sourced, computed, and verified.